Skip to main content
. 2022 Feb 11;145(5):1624–1631. doi: 10.1093/brain/awac052

Figure 2.

Figure 2

Comparison of disease onset and clinically relevant recovery rates of visual acuity in arLHON and mtLHON patients. (A) Reported age of onset for arLHON (n = 53, data unavailable for three patients) and mtLHON (n = 104). (B) Clinically relevant recovery rates for idebenone-treated (n = 30) and untreated (n = 16) arLHON patients (data presented for 46 of 56 arLHON patients with follow-up data available over at least 6 months following onset) and idebenone-treated (n = 184) and untreated (n = 88) mtLHON patients.